Tirzepatide's Triple Endpoint: Weight, Blood Pressure, Lipids

On August 13, 2026, PLOS ONE published a post hoc analysis of all four SURMOUNT trials that asks a question the original trials were not designed to answer: how often does one person on tirzepatide hit weight, blood pressure, and cholesterol targets at the same time? Across the four trials, 32% to 38% of participants taking tirzepatide reached all three at once, compared with 2% to 8% of participants on placebo. The analysis was funded by Eli Lilly and Company, which makes tirzepatide, and most of its authors are Lilly employees and shareholders.

That is a different question from the one most weight loss coverage answers, and it is worth understanding why.

What the triple endpoint measures

The analysis counted a participant as reaching the composite only if all three of these were true at the end of the trial:

• Body weight reduction of at least 5% from baseline
• Systolic blood pressure (the top number) down by at least 5 mmHg from baseline
• Non-HDL cholesterol below 130 mg/dL

Non-HDL cholesterol is the one most people have not heard of. It is total cholesterol minus HDL, which means it captures every cholesterol-carrying particle in your blood except HDL: LDL, VLDL, and the remnants in between. It is already on a standard lipid panel, or you can work it out from one you have.

Grouping the three together is not arbitrary. The FDA label for Zepbound, the brand of tirzepatide approved for chronic weight management, indicated it as of its original November 2023 version as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbid condition, and named hypertension and dyslipidemia among those conditions. The label has been revised since. As of its May 2026 version, it describes the population as adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, and it also carries a separate indication for moderate to severe obstructive sleep apnea in adults with obesity. Tirzepatide is a GIP and GLP-1 receptor agonist. In plain terms, the people prescribed it frequently arrive carrying all three problems at once, so whether the drug moves all three in the same person is a fair thing to ask.

What the analysis found

The analysis pooled SURMOUNT-1 (adults with obesity or overweight, without type 2 diabetes), SURMOUNT-2 (adults with obesity or overweight plus type 2 diabetes), SURMOUNT-3 (adults who had already completed an intensive lifestyle intervention), and SURMOUNT-4 (an open-label tirzepatide lead-in followed by a placebo-controlled period). Outcomes were assessed at week 72 in the first three trials and week 88 in SURMOUNT-4.

At the 5% weight threshold, 32% to 38% of tirzepatide-treated participants hit all three targets, versus 2% to 8% on placebo. Raising the weight bar did not collapse the composite as much as you might expect. At a 10% weight reduction the figures were 28% to 37% versus 1% to 5%, and at 15% they were 22% to 34% versus 1% to 3%. All comparisons were reported at p<0.001. Each range spans four different trials, so the low end and the high end are different study populations, not a margin of error.

Two things about the funding belong right next to those numbers. The analysis was supported by Eli Lilly and Company, which makes tirzepatide, and several of the authors are Lilly employees and shareholders. That does not make the arithmetic wrong. It does mean an industry-funded post hoc analysis chose which question to ask, and this was a question with a favorable answer.

Why counting people differs from averaging them

The parent trials already established that tirzepatide moves weight. In SURMOUNT-1, a phase 3 double-blind randomized trial of 2,539 adults with obesity or overweight and without diabetes, mean weight change at week 72 was -15.0%, -19.5%, and -20.9% across the three dose groups studied, versus -3.1% with placebo. That trial was also funded by Eli Lilly and Company.

But a trial average hides who got what. A study can report that mean blood pressure fell and mean cholesterol fell without those two improvements landing in the same participants. A composite endpoint closes that gap by counting individuals instead of means. That is the actual contribution here: not that tirzepatide moves three markers, which was already reported, but that in roughly a third of treated participants it moved all three past a target line together.

The limits, stated plainly

The authors call the analysis exploratory and hypothesis-generating, and they are right to.

• It is post hoc. The composite was defined after the trials had run and their results were known, not before.
• There was no adjustment for multiplicity, so those p-values carry less weight than they would in a pre-specified analysis.
• Participants entered these trials with cardiometabolic values that were already relatively normal, which limits what the results say about people at higher cardiovascular risk.
• The four trials had different designs and durations, so a pooled range is a summary, not a single result.

Most importantly, this counted markers, not events. No one in this analysis was followed for heart attacks or strokes. Clearing a cholesterol threshold is not the same as avoiding an outcome.

Trials that did count events are a separate body of evidence, and we have written about what 22 randomized trials found on tirzepatide and heart risk.

Tirzepatide also carries real risks. As of its May 2026 revision, the FDA label for Zepbound includes a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes such tumors in humans has not been determined. The label lists a contraindication in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and gastrointestinal side effects among the most common adverse reactions.

What this means if you are weighing it

If you are already taking tirzepatide, this analysis is a reason to watch your blood pressure and lipid panel alongside the scale, because in these trials those numbers moved together often enough to be worth measuring. A reasonable question for your provider: what were my systolic blood pressure and non-HDL cholesterol before I started, and what are they now?

If you are considering it, the honest framing is this. In these trials roughly a third of treated participants cleared all three thresholds, which means most did not. That is a meaningful probability, not a promise, and it was observed in people enrolled in a structured trial alongside diet and activity changes. Whether any of it applies to you depends on where your three numbers start, and that is a conversation for a licensed provider looking at your actual labs.